A biotechnology company Catamaran Bio Inc based in Cambridge has raised US$ 42 million financing in a Series A round on 23rd November 2020. This round is a part of their launch financing.
This funding round was led by Lightstone Ventures and Sofinnova Partners and included participation from the founding investor of Catamaran Bio, SV health investors. It also included participation from Astellas Venture Management and Takeda Ventures. They are planning to use this investment for advancing two of the company’s main CAR-NK i.e. Chimeric Antigen Receptor programs for cell therapy. They will invest in expanding their TAILWIND platform, which is a proprietary and integrated technologies suite for designing, manufacturing and genetically engineering CAR-NK therapies.
Catamaran Bio utilizes the natural cancer fighting properties present in NK cells and the incredible power of innovative non-viral cell engineering and synthetic biology for creating CAR-NK cell therapies. This is used in the treatment of more cancer types, particularly solid tumors and more patients. Their main focus is to bring the innovation in the field of cell therapy so that more patients can be treated. The scientific founders of the company; Dr. Catherine Bollard, MD and Branden Moriarty, PHD are pioneers of the NK cell biology which brings right knowledge to their platform. Also their team consists of deep expertise people who have a passion for developing revolutionary therapies.
The Chief Scientific Officer of Catamaran Bio, Vipin Suri said, “Catamaran is focused on expanding the domain of cell therapies for treating solid tumors and thereby providing transformative benefits to the cancer patients. We do this by the creation of allergenic cell therapies that use inborn cancer-fighting power present in the NK cells and by improving the cells by our biologically powerful attributes driven from our cutting edge technologies which originated from our TAILWIND platform.”
About Catamaran Bio
The Cambridge United States established biotechnology company Catamaran Bio was founded in 2020 and is involved in developing transforming CAR-NK cell therapies. It uses the genetic engineering power of natural killer cells for targeting therapeutic areas. They enable individuals and medical practitioners to procure therapies for treating cancer conditions. With their cutting edge approach and holistic way of developing cell therapies catamaran has created its own identity in the highly evolving NK cell domain with a platform that it complements their capability which is necessary for the development of CAR-NK based cell therapies.
We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!
[…] Next Story […]